Nycomed headquarters established in Zurich, Switzerland


Nycomed has moved into new corporate headquarters in Zurich and the Company’s headquarters function is now officially transferred from Denmark to Switzerland.

The new headquarters will be base for the majority of Nycomed’s central function heads and core teams, such as CEO, Integration, Commercial Operations, Legal, Human Resources, Business Development, Communications and Finance/Procurement. Employees from corporate functions in Denmark and Germany have already started relocation to Zurich.

Chief Executive Officer Håkan Björklund said: “It’s great to see the new headquarters finally operational, the hard work and preparations during the past few months have certainly been worthwhile.”

The new office facilities are located in the Zurich World Trade Centre close to the international airport and the city of Zurich. The office meets the requirements of a compact and functional headquarters that can accommodate up to 100 people.

Håkan Björklund continued: “I’m looking forward to moving into our new office. Zurich offers exactly the right environment for our headquarters. It is close to our largest market, Germany, and Konstanz, where our R&D function is led out of. At the same time our offices are close to an international airport. I’m confident our employees will feel comfortable here, which will help them be creative and focused on the further development of our business.”

Directions to the new Nycomed headquarters are available at I contact.

About Nycomed

Nycomed provides products for hospitals, specialists and general practitioners, as well as over-the-counter medicines in selected markets.

The company is active within a range of therapeutic areas, including cardiology, gastroenterology, osteoporosis, respiratory, pain and tissue management. New products are sourced both from own research and from external partners. Operating throughout Europe and in fast-growing markets such as Latin America, Russia/CIS and the Asia-Pacific region Nycomed has a presence in about 50 markets worldwide.

Privately owned, the combined group had non-audited estimated annual sales of approximately € 3.4 billion and an EBITDA of € 933.4 million (2006 results).

For more information visit

For further information

    Christoffer Jensen, VP Communications
    Phone: +45 46 77 11 12
    Mobile: +45 22 43 69 44

    Susanne Hof, Head of External Communications
    Phone: +49 7531 84 30 59
    Mobile: +49 151 55 00 26 65



For further information

General phone:

+41 44 555 15 10
Beatrix Benz,

phone: +41 44 555 1508
Tobias Cottmann,

phone: +41 44 555 1501

Christian B. Seidelin,

phone: +41 44 555 11 04

Related information

English PDF
Danish PDF
German PDF

Top of page

Takeda Pharma